On the downside, the area between 18,133 and 18,080 represents a significant demand zone. As long as Nifty trades above 18,080, the general bullish texture will hold, but below 18,080, we can anticipate a short-term trend reversal,” Santosh Meena, Head of Research, Swastika Investmart Ltd., said.

“The near-term market construct is not favourable for equities. The rising Covid cases in the US, Korea, Brazil, and China is an area of concern. The situation is dire in China. This might impact market sentiments,” V K Vijayakumar, Chief Investment Strategist at Geojit Financial Services said.

In the highly concentrated long-term portfolio, almost all stocks have compounded their share prices at 15-30% annually demonstrating that stock selection contributed significantly to portfolio returns, the PMS fund said.

"The IT sector has been a pleasant surprise as far as the results are concerned. Top-line growth across most major companies has come in better than expected whereas attrition pressures have also eased, thus keeping both the growth as well as margins healthy. This, combined with attractive valuations, makes the sector a good bet from a 2-3 year perspective."

Dr Lal PathLabs shares gained 1.7 percent to Rs 2,694.35, continuing uptrend for the seventh consecutive session. It has seen formation of bullish candle on the daily charts with higher high higher low formation for seven straight sessions, and has given a breakout of downward sloping resistance trend line adjoining April 8 and August 26.

The global investment bank expects Emami's growth to recover from H2FY23 after a very high base. Margin pressures will persist in the near term, it said. It marginally lowered FY23/24/25 EPS by 2-3 per cent. Emami trades at 26x FY24 earnings ~40 per cent discount to the peers, said the note.

The company is pivoting from a prescription manufacturing service to an original device manufacturer (ODM) for smart TVs, having acquired sub-licensing rights for Google TV and Android TV from Google. The rights, announced by Dixon on Monday, will enable the firm to both design and manufacture smart LED TVs for third-party brands.

Gurgaon-headquartered Dr Lal PathLabs and other diagnostic chains are feeling the heat due to the big drop in demand for Covid-19 testing, competition intensifying with the entry of e-pharmacies, web aggregators and pharma companies into diagnostics, resulting in a price war at a time when inflation pressure is high.

Gurgaon-headquartered Dr Lal PathLabs and other diagnostic chains are feeling the heat due to the big drop in demand for Covid-19 testing, competition intensifying with the entry of e-pharmacies, web aggregators and pharma companies into diagnostics, resulting in a price war at a time when inflation pressure is high.

Dr Lal PathLabs witnessed an ascending triangle pattern breakout on July 29 which was placed above Rs 2,250 levels in the daily time frame. After breakout, prices are showing a gradual upside movement in a small steep formation.

The company had reported a net profit of Rs 134 crore in the April-June period of the last fiscal.Revenue from operations declined to Rs 503 crore in the period under review from Rs 607 crore a year ago, Dr Lal PathLabs said in a regulatory filing.

Indra Nooyi is the richest professional manager with Rs 5K cr wealth.

Ahmedabad-based drug major Torrent Pharma is reportedly set to foray into the diagnostics business, although a formal announcement is awaited. Last year, its Mumbai-based peer Lupin made an organic foray into the ₹70,000-crore sector. Mankind Pharma and Reliance Life Sciences are other large players that have entered the sector.

As per the ABDM website, more than 22.33 crore health IDs have been created, 62,182 health facilities registered, 14,840 doctors registered, more than 5.43 lakh downloads of the Health Records App has been done, 867 integrators are active out of which 40 of them have been successful.

Three of them have turned multibaggers and Bloomberg’s consensus rating shows that all the seven stocks still have some steam left